The University of Southampton
University of Southampton Institutional Repository

JAK2(V617F) mutational load in patients with Polycythemia Vera (PV) measured by peripheral blood DNA is associated with disease severity

JAK2(V617F) mutational load in patients with Polycythemia Vera (PV) measured by peripheral blood DNA is associated with disease severity
JAK2(V617F) mutational load in patients with Polycythemia Vera (PV) measured by peripheral blood DNA is associated with disease severity
Different methods using peripheral blood RNA (Vannucchi AM, et al. Leukemia. 2007,1–8), or archival bone marrow DNA (Tefferi A, et al. Leukemia. 2007,1–2) have yielded varied results correlating allele burden with severity and duration of disease. We therefore aimed to determine whether JAK2V617F allele burden correlated with certain parameters of disease. At our institution, 105 patients were diagnosed according to the criteria of the Polycythemia Vera Study Group. We grouped their JAK2V617F allele burdens into quintiles. DNA from peripheral blood was analyzed using pyrosequencing. For those patients whose allele burden was <5%, a sensitive ARMS (amplification refractory mutation system) assay was performed to demonstrate the presence of the JAK2V617F allele. Duration of disease was assessed from onset of symptoms. Spleen size was measured in cm below the midpoint of the left costal margin in the midclavicular line and categorized as not enlarged, slightly (1–3 cm), moderately (4–9 cm), or grossly enlarged (>9 cm). Thrombotic events were recorded within 5 years of JAK2V617F determination. There were 52 men and 53 women. The patients ranged in age from 35 to 88 years, median 60 years. The median duration of disease was 7.4 years (range: 0.2 - 36.6 years), and the median duration of follow-up after JAK2V617F determination was 12 months year (range: 1 - 43 months). The mean mutant allele burden was 46.0% (s.d. ± 29.7%). The fifth, and highest quintile had a mean mutant allele burden of 90.2% (s.d. ± 5.8%); the lowest quintile had a mean mutant allele burden of 9.9% (s.d. ± 6.3%). JAK2V617F did not correlate with age, gender, hematocrit and platelet count at diagnosis, or rate of phlebotomy prior to cytoreductive therapy. Increasing JAK2V617F burden did correlate with higher WBC at diagnosis (P=0.02), degree of splenomegaly (P<0.0001), presence of marrow fibrosis (P=0.03), and longer duration of disease (P=0.001). There was a trend for a higher JAK2V617F allele burden among patients with venous compared to arterial thrombosis. When the subset of patients who had JAK2V617F testing performed within 5 years of diagnosis (N=35) was examined, trends similar to those we had reported for all 105 patients were found, but no definitive statement can be made because of the small sample size. We noted a JAK2V617F allele burden of more than 80% during the course of the illness was associated with a significant disease phenotype. This is the first report of increased marrow fibrosis associated with high JAK2V617F burden. The importance of using quantitative JAK2V617F for assessing allele burden is stressed because patients with an increased allele burden may be candidates for anti-JAK therapy.
hematology, disease, polycythemia vera, dna, england, leukemia, blood, patients, time
0006-4971
p.746A
Silver, Richard T.
661e0b91-4a5c-4100-9a7a-e4f1db3f3a1d
Vandris, Katherine
42852a40-1f83-4d34-bd50-78dd60d14335
Wang, Y. Lynn
281a4bfb-c4f7-4bb1-b883-902d17f0e04c
Christos, Paul J.
96cfe9aa-78f7-4cb9-ab37-e08b2c531f57
Adriano, Fernando
e4ad50a6-b9db-453c-8b12-0e282d6f4fcd
Jones, Amy V.
3d296088-a099-45cf-b227-541ff59d800c
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Silver, Richard T.
661e0b91-4a5c-4100-9a7a-e4f1db3f3a1d
Vandris, Katherine
42852a40-1f83-4d34-bd50-78dd60d14335
Wang, Y. Lynn
281a4bfb-c4f7-4bb1-b883-902d17f0e04c
Christos, Paul J.
96cfe9aa-78f7-4cb9-ab37-e08b2c531f57
Adriano, Fernando
e4ad50a6-b9db-453c-8b12-0e282d6f4fcd
Jones, Amy V.
3d296088-a099-45cf-b227-541ff59d800c
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4

Silver, Richard T., Vandris, Katherine, Wang, Y. Lynn, Christos, Paul J., Adriano, Fernando, Jones, Amy V. and Cross, Nicholas C.P. (2007) JAK2(V617F) mutational load in patients with Polycythemia Vera (PV) measured by peripheral blood DNA is associated with disease severity. Blood, 110 (11), p.746A.

Record type: Article

Abstract

Different methods using peripheral blood RNA (Vannucchi AM, et al. Leukemia. 2007,1–8), or archival bone marrow DNA (Tefferi A, et al. Leukemia. 2007,1–2) have yielded varied results correlating allele burden with severity and duration of disease. We therefore aimed to determine whether JAK2V617F allele burden correlated with certain parameters of disease. At our institution, 105 patients were diagnosed according to the criteria of the Polycythemia Vera Study Group. We grouped their JAK2V617F allele burdens into quintiles. DNA from peripheral blood was analyzed using pyrosequencing. For those patients whose allele burden was <5%, a sensitive ARMS (amplification refractory mutation system) assay was performed to demonstrate the presence of the JAK2V617F allele. Duration of disease was assessed from onset of symptoms. Spleen size was measured in cm below the midpoint of the left costal margin in the midclavicular line and categorized as not enlarged, slightly (1–3 cm), moderately (4–9 cm), or grossly enlarged (>9 cm). Thrombotic events were recorded within 5 years of JAK2V617F determination. There were 52 men and 53 women. The patients ranged in age from 35 to 88 years, median 60 years. The median duration of disease was 7.4 years (range: 0.2 - 36.6 years), and the median duration of follow-up after JAK2V617F determination was 12 months year (range: 1 - 43 months). The mean mutant allele burden was 46.0% (s.d. ± 29.7%). The fifth, and highest quintile had a mean mutant allele burden of 90.2% (s.d. ± 5.8%); the lowest quintile had a mean mutant allele burden of 9.9% (s.d. ± 6.3%). JAK2V617F did not correlate with age, gender, hematocrit and platelet count at diagnosis, or rate of phlebotomy prior to cytoreductive therapy. Increasing JAK2V617F burden did correlate with higher WBC at diagnosis (P=0.02), degree of splenomegaly (P<0.0001), presence of marrow fibrosis (P=0.03), and longer duration of disease (P=0.001). There was a trend for a higher JAK2V617F allele burden among patients with venous compared to arterial thrombosis. When the subset of patients who had JAK2V617F testing performed within 5 years of diagnosis (N=35) was examined, trends similar to those we had reported for all 105 patients were found, but no definitive statement can be made because of the small sample size. We noted a JAK2V617F allele burden of more than 80% during the course of the illness was associated with a significant disease phenotype. This is the first report of increased marrow fibrosis associated with high JAK2V617F burden. The importance of using quantitative JAK2V617F for assessing allele burden is stressed because patients with an increased allele burden may be candidates for anti-JAK therapy.

This record has no associated files available for download.

More information

Published date: 16 November 2007
Additional Information: ASH Annual Meeting Abstracts, Poster Session: Myeloproliferative Syndromes. Abstract 2530.
Keywords: hematology, disease, polycythemia vera, dna, england, leukemia, blood, patients, time

Identifiers

Local EPrints ID: 60240
URI: http://eprints.soton.ac.uk/id/eprint/60240
ISSN: 0006-4971
PURE UUID: 36fdcc7f-6cdb-4eed-a90f-ae2a839c5522
ORCID for Nicholas C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 11 Nov 2008
Last modified: 12 Dec 2021 03:17

Export record

Contributors

Author: Richard T. Silver
Author: Katherine Vandris
Author: Y. Lynn Wang
Author: Paul J. Christos
Author: Fernando Adriano
Author: Amy V. Jones

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×